POPS: A Trial Assessing Post-Operative Use of ProSpare, a Rectal Obturator in Prostate Cancer Radiotherapy

Sponsor
Royal Marsden NHS Foundation Trust (Other)
Overall Status
Recruiting
CT.gov ID
NCT02978014
Collaborator
Institute of Cancer Research, United Kingdom (Other)
245
10
2
94.7
24.5
0.3

Study Details

Study Description

Brief Summary

A two-arm randomised controlled trial in patients receiving post-prostatectomy radiotherapy in the adjuvant or salvage setting, with patients randomised to receive daily ProSpare (obturator) guided IMRT or Centre standard (non-obturator) guided IMRT.

Condition or Disease Intervention/Treatment Phase
  • Device: ProSpare
Phase 2

Detailed Description

Surgery to remove the prostate gland is one of the ways of treating prostate cancer. Some patients receive radiotherapy after surgery if the cancer may not have been completely removed. Radiotherapy to the area where the prostate was can cause side effects, which can cause bowel and bladder symptoms as well as reducing sexual function.

Radiotherapy alone is also a standard treatment for prostate cancer. At the Royal Marsden Hospital and Institute of Cancer Research the investigators have designed and patented a device called ProSpare to improve the accuracy of radiotherapy. The device has already been developed and tested in over 80 patients having prostate radiotherapy and was well tolerated. Treatment accuracy was improved and the radiation dose to the rectum was reduced. Patients have given very valuable feedback and comments about ProSpare's design and use, which the investigators have incorporated in the final design. It is now important to test ProSpare in a multi-centre randomised controlled trial. The investigators aim to determine whether ProSpare will reduce the side effects reported by patients having radiotherapy after prostatectomy.

The ProSpare device is inserted by the patient into the rectum for each daily radiotherapy treatment. The disposable device stays in place for about 15 minutes each day. The curve in the device is designed to follow the shape of the rectum and it stays in the correct place by securely locating in the anal sphincter. ProSpare contains small "markers" - steel ball bearings - which can be "seen" on the standard scans taken before a radiotherapy treatment. Treatment is adjusted before each daily treatment to account for patient movement and radiotherapy set-up variation. As a result, treatment is more accurate than using the standard methods of radiotherapy localisation. This means the radiotherapy "safety margins" which are placed around the prostate bed can be reduced. The dose to the rectum and bladder as well as the structures that are associated with erectile function will be reduced. This may lead to an improvement in the side effects caused by radiotherapy.

Other ways to identify the treatment target area for such image guided radiotherapy (IGRT) includes the insertion of fiducial markers - usually in the form of gold seeds into the prostate or prostate bed. This has become standard practice in some radiotherapy centres for prostate radiotherapy but is technically complex for prostate bed radiotherapy and not routinely used. ProSpare has the additional advantage of being non-invasive and without the risk of infection associated with fiducial insertion.

Patients will be randomly selected to either have standard treatment or use ProSpare daily with adjusted set-up margins. During and after treatment, patients will be asked questions and given questionnaires to complete, asking about bowel, urinary and sexual function. The investigators will look at the results in each group and see if treatment with ProSpare has a benefit in improving the side effects from radiotherapy. If a benefit is seen, the aim will be for ProSpare guided radiotherapy to become part of the standard treatment for prostate bed radiotherapy nationally and internationally.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
245 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Randomised Controlled Phase II Trial Assessing Post-Operative Use of ProSpare, a Rectal Obturator in Prostate Cancer Radiotherapy
Actual Study Start Date :
Feb 8, 2017
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: ProSpare Arm

ProSpare (obturator) image guided IMRT (i.e. radiotherapy administered to patients with the ProSpare device inserted in the rectum)

Device: ProSpare
A novel rectal obturator (ProSpare) acting as a non-invasive daily on-line image guided tool, a rectal spacer and a prostate bed stabiliser
Other Names:
  • Rectal obturator
  • No Intervention: Non-ProSpare Arm

    Standard of Care (non-obturator) image guided IMRT (i.e. radiotherapy administered to patients without the ProSpare device inserted in the rectum)

    Outcome Measures

    Primary Outcome Measures

    1. EPIC Bowel Scores for Bowel, Urinary and Sexual domains [Two years]

      Difference between groups in EPIC scores

    Secondary Outcome Measures

    1. Quality of Life measures [Two and Five years]

      Six Patient Reported Outcome Measure (PROM) questionnaires

    2. Dosimetric analysis [Two years]

      Analysis of dose/toxicity axis

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion criteria:
    1. Patient has undergone radical prostatectomy

    2. Histologically confirmed prostatic cancer

    3. Patient due to receive post-operative prostate bed radiotherapy either in the adjuvant or salvage* setting

    4. WHO performance status 0-1 at randomization

    5. Age > 18 years

    6. Written informed consent

    7. Able to independently complete patient questionnaires

    Exclusion Criteria:
    1. Lymph node or distant metastases from prostate cancer

    2. Prior pelvic radiotherapy

    3. Previous invasive cancer in the past 3 years, with the exception of non-melanoma skin cancer

    4. Symptomatic haemorrhoids or other anal conditions which affect adequate insertion and retention of the rectal obturator

    5. Planned chemotherapy within 2 months of completion of adjuvant or salvage radiotherapy

    6. Musculoskeletal conditions which limit flexibility or mobility and will make patient self insertion of ProSpareā„¢ difficult

    7. Comorbid conditions likely to impact on advisability of prostate bed radiotherapy (e.g. inflammatory bowel disease, previous colorectal surgery, significant bladder instability or urinary incontinence)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Beacon Centre, Musgrove Park Hospital Taunton Somerset United Kingdom TA1 5DA
    2 The Royal Marsden NHS Foundation Trust Sutton Surrey United Kingdom SM2 5PT
    3 Cambridge University Hospitals Cambridge United Kingdom CB2 0QQ
    4 Royal Surrey County Hospital NHS Foundation Trust Guildford United Kingdom GU2 7XX
    5 East Suffolk and North Essex NHS Trust Ipswich United Kingdom IP4 5PD
    6 University College London Hospitals NHS Foundation Trust London United Kingdom NW1 2PG
    7 Royal Free Hampstead NHS Trust London United Kingdom NW3 2QG
    8 The Royal Marsden NHSFT London United Kingdom SW3 6JJ
    9 East and North Hertfordshire NHS Trust, Mount Vernon Cancer Centre Middlesex United Kingdom HA6 2RN
    10 Norfolk and Norwich University Hospital NHSFT Norwich United Kingdom NR4 7UY

    Sponsors and Collaborators

    • Royal Marsden NHS Foundation Trust
    • Institute of Cancer Research, United Kingdom

    Investigators

    • Principal Investigator: Dr Julia Murray, Royal Marsden Hospital / Institute of Cancer Research

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Royal Marsden NHS Foundation Trust
    ClinicalTrials.gov Identifier:
    NCT02978014
    Other Study ID Numbers:
    • CCR 4359
    First Posted:
    Nov 30, 2016
    Last Update Posted:
    Apr 19, 2021
    Last Verified:
    Apr 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Royal Marsden NHS Foundation Trust
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 19, 2021